Ben Van Baelen

1.6k total citations
13 papers, 826 citations indexed

About

Ben Van Baelen is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Ben Van Baelen has authored 13 papers receiving a total of 826 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 9 papers in Virology and 4 papers in Epidemiology. Recurrent topics in Ben Van Baelen's work include HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (9 papers) and HIV/AIDS Research and Interventions (6 papers). Ben Van Baelen is often cited by papers focused on HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (9 papers) and HIV/AIDS Research and Interventions (6 papers). Ben Van Baelen collaborates with scholars based in United States, Belgium and South Africa. Ben Van Baelen's co-authors include Gastón Picchio, Éric Lefebvre, Sandra De Meyer, Marie‐Pierre de Béthune, Tony Vangeneugden, Els De Paepe, Maria Beumont, Herwig Van Marck, Nyasha Bakare and Francesca Conradie and has published in prestigious journals such as Gastroenterology, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Ben Van Baelen

13 papers receiving 806 citations

Peers

Countries citing papers authored by Ben Van Baelen

Since Specialization

Citations

This map shows the geographic impact of Ben Van Baelen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben Van Baelen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben Van Baelen more than expected).

Fields of papers citing papers by Ben Van Baelen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ben Van Baelen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben Van Baelen. The network helps show where Ben Van Baelen may publish in the future.

Co-authorship network of co-authors of Ben Van Baelen

This figure shows the co-authorship network connecting the top 25 collaborators of Ben Van Baelen. A scholar is included among the top collaborators of Ben Van Baelen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ben Van Baelen. Ben Van Baelen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction 2022 ·Clinical Infectious Diseases ·John Steytler, Charles Craig, Elna van der Ryst, Ben Van Baelen, Jeremy Nuttall, Neliëtte van Niekerk, John W. Mellors, Urvi M. Parikh, Carole L. Wallis, (unknown)	3
2	Clinical Presentation, Treatment Response, and Virology Outcomes of Women Who Seroconverted in the Dapivirine Vaginal Ring Trials—The Ring Study and DREAM 2022 ·Clinical Infectious Diseases ·John Steytler, Elna van der Ryst, Charles Craig, Ben Van Baelen, Jeremy Nuttall, Neliëtte van Niekerk, John W. Mellors, Urvi M. Parikh, Carole L. Wallis, (unknown)	1
3	Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study 2021 ·The Lancet HIV ·Annaléne Nel, Neliëtte van Niekerk, Ben Van Baelen, (unknown), (unknown), Allison Carter, John Steytler, Elna van der Ryst, Charles Craig, Cheryl Louw, (unknown), Zonke Mabude, Philip Kotze, (unknown), Hugo Tempelman, Katherine Gill, Sylvia Kusemererwa, Linda‐Gail Bekker, Bríd Devlin, Zeda Rosenberg	71
4	Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial 2017 ·SAGE Open Medicine ·Eduardo Arathoon, As’ad E. Bhorat, (unknown), Herta Crauwels, Ludo Lavreys, Lotke Tambuyzer, Ben Van Baelen, Simon Vanveggel, Magda Opsomer	1
5	Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis 2015 ·European Respiratory Journal ·Alexander S. Pym, Andreas H. Diacon, Shenjie Tang, Francesca Conradie, Manfred Danilovitš, Charoen Chuchottaworn, I. А. Vаsilyevа, Koen Andries, Nyasha Bakare, Tine De Marez, (unknown), Nacer Lounis, Paul Meyvisch, Ben Van Baelen, Rolf P. G. van Heeswijk, Brian Dannemann	226
6	Comparison of Genotypic and Phenotypic HIV Type 1 Tropism Assay: Results from the Screening Samples of Cenicriviroc Study 202, a Randomized Phase II Trial in Treatment-Naive Subjects 2013 ·AIDS Research and Human Retroviruses ·Ron M. Kagan, Erik P. Johnson, M F Siaw, Ben Van Baelen, Richard C. Ogden, Jamie L. Platt, Rick L. Pesano, Éric Lefebvre	12
7	Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial 2012 ·Hepatology ·Sandra De Meyer, Inge Dierynck, Anne Ghys, Maria Beumont, (unknown), Ben Van Baelen, James C. Sullivan, (unknown), Tara L. Kieffer, Stefan Zeuzem, Gastón Picchio	35
8	Telaprevir-Related Dermatitis 2012 ·JAMA Dermatology ·Jean‐Claude Roujeau, Maja Mockenhaupt, Steven R. Tahan, Joshua Henshaw, Emily C. Martin, (unknown), Ben Van Baelen, Leif Bengtsson, Priya Singhal, Robert S. Kauffman, Robert S. Stern	43
9	Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections 2011 ·Gastroenterology ·Graham R. Foster, Christophe Hézode, Jean–Pierre Bronowicki, Giampiero Carosi, Ola Weiland, (unknown), Rolf van Heeswijk, Ben Van Baelen, Gastón Picchio, Maria Beumont	134
10	Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients 2009 ·AIDS ·Sandra De Meyer, Erkki Lathouwers, Inge Dierynck, Els De Paepe, Ben Van Baelen, Tony Vangeneugden, Sabrina Spinosa‐Guzman, Éric Lefebvre, Gastón Picchio, Marie‐Pierre de Béthune	46
11	Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents 2009 ·AIDS ·Stéphane Blanche, Rosa Bologna, Pedro Cahn, Sorin Rugină, Patricia M. Flynn, Clàudia Fortuny, Peter Vis, Vanitha Sekar, Ben Van Baelen, Inge Dierynck, Sabrina Spinosa‐Guzman	37
12	Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials 2008 ·AIDS Research and Human Retroviruses ·Sandra De Meyer, Tony Vangeneugden, Ben Van Baelen, Els De Paepe, Herwig Van Marck, Gastón Picchio, Éric Lefebvre, Marie‐Pierre de Béthune	121
13	Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients 2007 ·AIDS ·Richard Haubrich, (unknown), Philippe Chiliade, Amy E. Colson, Marcus A. Conant, Joel E. Gallant, Timothy Wilkin, Jeffrey P. Nadler, Gerald Pierone, Michael S. Saag, Ben Van Baelen, Éric Lefebvre	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact